Oncocyte Corporation Common Stock

Oncocyte Corporation announced that its GraftAssure research assay has been adopted by two leading transplant university hospitals in the U.S. and Germany. The company has also submitted a plan for an IVD version of its dd-cfDNA kitted test to the FDA, marking a critical step in the product development process.

Related tickers: OCX.

Oncocyte Corporation announced a $10.2 million private placement of securities, with participation from new and existing investors, including strategic partner Bio-Rad Laboratories. The company plans to use the proceeds for working capital and general corporate purposes.

Related tickers: OCX, BIO, BIO.B.